Pharmaceuticals
YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR
SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The trial has completed dosing in eight participants, including ...
2024-12-21 16:23
1854
United Imaging Intelligence at RSNA 2024: Empowering a More Intelligent and Connected World with Medical AI
CHICAGO, Dec. 20, 2024 /PRNewswire/ -- As RSNA 2024 concluded, United Imaging Intelligence (UII), a subsidiary of United Imaging Group specializing in medical AI, made a significant impression with a visionary showcase that seamlessly aligned with the event's theme: "Building Intelligent Connecti...
2024-12-20 22:00
1001
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr.Lilly Xu as its new Chief Technology Officer (CTO). With over30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation and ...
2024-12-20 21:30
894
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
* Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY * Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY * Gross margin increased to 82.6% from 80.9% in the same period of FY2024 * Total operating expenses decreased to RMB 276.4 million, down 31.6%...
2024-12-19 22:05
1660
BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development
CHENGDU, China, Dec. 19, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr. Xin Zhanchang, Chairman of the Board of Directors of BGM Group and Chairman of Gansu Qilianshan Pharmaceutical Co., Ltd., led the sales team to visit their long-term strategic partner, Jointow...
2024-12-19 21:30
1326
LG Corp. Chairman and CEO Kwang Mo Koo sends 2025 New Year Address to 270,000 global employees on December 19
* "Let's Shape LG's Future with the DNA of Challenge and Change We've had Since Day 1" * Highlighting LG's Spirit – the DNA of challenge and change since Day 1 - "LG's Day 1 spirit of choosing what others wouldn't dare comes from our DNA of challenge and change as we serve our customer...
2024-12-19 13:00
1081
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS")China on December 16th. The partnership was officially formalized with the signing of a colla...
2024-12-19 12:40
923
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer. * The product, termed SAR-bisFAP, has shown strong tumour targeting...
2024-12-18 22:03
1278
Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery
- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic develop...
2024-12-18 13:09
1576
U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
* STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) * STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio a...
2024-12-18 11:50
843
Complete Genomics Adds Eurofins Clinical Enterprise, LLC to its Sequencing Service Provider Program
FRAMINGHAM, Mass., Dec. 17, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, California based genomics tools manufacturer, today announced Framingham, Massachusetts based Eurofins Clinical Enterprise, LLC as the newest addition to its Sequencing Service Provider Program. Complete Genomics'...
2024-12-17 22:00
784
Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary
Agreement to Deliver Critical Medicines ITASCA, Ill., Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on theAsia-Pacific market is pleased to announce that Hupan Phar...
2024-12-17 21:30
1385
Great Bay Bio Completes First Close of Series B Financing
HONG KONG, Dec. 17, 2024 /PRNewswire/ -- Great Bay Bio (GBB) is thrilled to announce the successful first close of its Series B financing round. This milestone was achieved with the round led by a syndication of a well-known strategic investment institution and its affiliate, Tiger Jade Pebble A...
2024-12-17 16:42
1104
SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals
SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small protein-based radiopharmaceuticals on safety and ef...
2024-12-17 08:20
1091
Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index
* Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 16, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contr...
2024-12-17 07:51
1189
Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers
CAMBRIDGE, Mass., Dec. 16, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM ), today announced a research collaboration and license agreement to discover next-generation T-cell engagers ("TCEs") with Candid Therapeutics, ...
2024-12-16 20:03
834
Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS
PRINCETON, N.J. and SUZHOU, China, Dec. 12, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...
2024-12-13 08:00
1317
CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...
2024-12-12 21:00
1306
Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.
CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma
Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life
Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").
2024-12-12 21:00
1378
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...
2024-12-12 21:00
1631
Week's Top Stories
Most Reposted
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
[Picked up by 322 media titles]
2024-12-19 13:41
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
[Picked up by 305 media titles]
2024-12-19 17:56
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 304 media titles]
2024-12-20 16:25
ADA Acquires Customore, Launching the Most Advanced Intelligent Commerce Solution for the CPG Industry
[Picked up by 296 media titles]
2024-12-17 11:00
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 295 media titles]
2024-12-20 18:11
Most Read
ADA Acquires Customore, Launching the Most Advanced Intelligent Commerce Solution for the CPG Industry
2024-12-17 11:00
4099
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
2024-12-19 17:56
3902
Dhaka Court Dismisses Allegations Against Nagad Founder Tanvir A Mishuk
2024-12-16 18:32
3811
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
2024-12-19 13:41
3624
HUAWEI FreeBuds Pro 4: HUAWEI SOUND Elevating TWS Flagship Experience to New Heights
2024-12-15 00:04
3541
